Biopharma · FDA Approvals · Stock
DHR Danaher
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries aft…
Assets on file: Xpert Respiratory Panel
Catalyst calendar
Dated catalysts for DHR, including recently decided ones.
Nothing scheduled in this window.
Recent first-hand events
Every first-hand event for DHR, newest first.
DHRDanaherCepheid Xpert Respiratory Panel receives FDA clearance
Cepheid received FDA 510(k) clearance for the Xpert Respiratory Panel, a multiplex PCR test that detects 13 common viral and bacterial respiratory pathogens from a single nasopharyngeal swab. The test is indicated to aid in the diagnosis of respiratory tract infection when used with other clinical and laboratory findings. It will begin shipping to U.S. customers in the coming weeks and runs on existing GeneXpert systems.
Peers by market cap
Companies in the same sector closest to DHR in market value.
PFEPfizerMarket cap $173.4B · 12 tracked drugs · 36 upcoming catalysts
NVONovo NordiskMarket cap $174.0B · 3 tracked drugs · 9 upcoming catalysts
ABTAbbottMarket cap $177.4B · 3 tracked drugs · 1 upcoming catalyst
VRTXVertex PharmaceuticalsMarket cap $136.1B · 5 tracked drugs · 11 upcoming catalysts
BMYBristol-Myers SquibbMarket cap $128.7B · 11 tracked drugs · 61 upcoming catalysts
GILDGileadMarket cap $194.9B · 10 tracked drugs · 34 upcoming catalysts
MDTMedtronicMarket cap $123.6B · 2 tracked drugs
GSKGSKMarket cap $102.6B · 2 tracked drugs · 2 upcoming catalysts